Pemetrexed is an antifolate metabolite used to treat non-small cell lung cancer in the adjuvant and advanced setting. It is commonly known to cause rash, diarrhea, fatigue, mucositis, and myelosuppression. We report a case of a patient receiving adjuvant cisplatin and pemetrexed for non-small cell lung adenocarcinoma and experienced severe rhabdomyolysis.
KreuterMVansteenkisteJFischerJR, et al.Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol2013; 24: 986–992.
2.
ScagliottiGVParikhPvon PawelJ, et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol2008; 26: 3543–3551.
3.
HuangMSTsaiJRShenMC, et al.Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. Lung Cancer2012; 76: 491–492.
4.
CeribelliACecereFLMilellaM, et al.Severe rhabdomyolysis associated with pemetrexed-based chemotherapy. Lancet Oncol2006; 7: 353–353.
5.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
